8-K: Cycurion Faces Nasdaq Delisting, Appeals Decision

Cycurion, Inc. received a Nasdaq delisting determination, appealed the decision, and plans a reverse stock split while also announcing new contracts and legal action against market manipulation.

Summary

• Received a Delisting Determination Letter from Nasdaq on October 14, 2025, due to failure to comply with the minimum $1.00 bid price rule by the October 6, 2025 deadline.
• Submitted an appeal to a Nasdaq Hearings Panel on October 20, 2025, which will stay the delisting process pending the Panel's decision.
• The Board of Directors approved a 30:1 reverse stock split on October 10, 2025, expected to take effect on October 27, 2025, to regain compliance with the bid price rule.
• Engaged counsel on October 14, 2025, to pursue legal remedies, including a "John Doe" lawsuit, against individuals disseminating false information, defaming the company and executives, and indications of unlawful naked short selling.
• Announced the closure of five new contracts in September, totaling approximately $1 million, expected to generate an additional $75,000 in monthly recurring revenue, with four contracts in the healthcare and pharmaceutical sectors.

Sentiment

Score: 3

Explanation: The immediate threat of Nasdaq delisting and the need for a significant reverse stock split are major negative indicators, overshadowing the positive news of new contracts and legal action against market manipulation. While the company is fighting for its listing and addressing perceived manipulation, the fundamental issue of its low stock price and non-compliance remains critical and creates significant uncertainty for investors.

Positives

• Secured five new contracts totaling approximately $1 million in value.
• Expected to generate an additional $75,000 in monthly recurring revenue.
• Successful expansion into commercial and non-government sectors, particularly healthcare and pharmaceutical industries.
• Initiated legal action, including a "John Doe" lawsuit, against individuals spreading misinformation, defamation, and potential unlawful naked short selling.
• The appeal request to Nasdaq stays the immediate delisting and provides an opportunity to present its case.

Negatives

• Received a Delisting Determination Letter from Nasdaq due to failure to maintain the minimum $1.00 bid price.
• The common stock is subject to delisting from The Nasdaq Global Market.
• If the appeal is unsuccessful or compliance is not regained, shares may be delisted and potentially moved to the less liquid over-the-counter market.
• Trading on the over-the-counter market could depress the trading price and reduce liquidity for stockholders.
• The need for a 30:1 reverse stock split indicates a significantly low stock price.

Risks

• Failure to regain compliance with Nasdaq's continued listing standards.
• Unsuccessful appeal to the Nasdaq Hearings Panel, leading to delisting.
• Potential transfer of common stock to the over-the-counter market, resulting in significantly less liquidity and depressed trading prices.
• No assurance of continued trading on the over-the-counter market or sufficient trading volume.
• Inability to service or otherwise pay debt obligations, including to holders of convertible notes.
• Market acceptance of new service offerings.
• Ability to expand services for existing customers and acquire new customers.
• Sufficiency of capital to operate as anticipated.
• Demand for products and general economic activity.
• Outcomes of the company's investigations and any potential legal proceedings, including the "John Doe" lawsuit.
• Future performance of the company's stock.

Future Outlook

The company plans to appeal Nasdaq's delisting determination, with a hearing expected within 30-45 days. A 30:1 reverse stock split is anticipated to take effect on October 27, 2025, aimed at regaining compliance with the bid price rule. If delisted, the company may seek to list its shares on the over-the-counter market. Management also expects further expansions and contract announcements in the coming quarters and is pursuing legal action against market manipulation.

Management Comments

• "We are deeply concerned about the harm inflicted on our shareholders by coordinated efforts to spread misinformation and manipulate our stock price." Kevin Kelly, Chairman and CEO.
• "Cycurion has been a highly active stock on NASDAQ, yet it has experienced unexplained volatility despite our strong operational achievements and innovations in cybersecurity." Kevin Kelly.
• "This announcement underscores our zero-tolerance policy toward manipulative behaviors online or in the markets." Kevin Kelly.
• "We believe the Company and its dedicated shareholders have been unfairly targeted by these bad actors, particularly at our current stock price, which we view as undervalued given our robust intellectual property portfolio and substantial backlog of contracts." Kevin Kelly.
• "This milestone reflects our deliberate strategy, as communicated to the market, to accelerate expansion into commercial and non-government sectors." Kevin Kelly.
• "These wins not only validate our approach but also position Cycurion for sustained revenue growth." Kevin Kelly.

Industry Context

The cybersecurity industry continues to be a critical sector, with increasing demand for robust solutions across government and commercial clients. Cycurion's expansion into healthcare and pharmaceutical sectors aligns with the growing need for data protection in these sensitive industries. The company's allegations of market manipulation and naked short selling highlight ongoing concerns within financial markets regarding integrity and fair trading practices, particularly for smaller-cap companies.

Comparison to Industry Standards

• The filing does not provide specific financial or operational benchmarks against comparable companies or industry standards to allow for a detailed assessment of its results in a global context.
• While the new contracts represent growth, their scale relative to the broader cybersecurity market or specific competitors is not detailed.
• The company's stock performance, leading to delisting concerns, suggests underperformance relative to Nasdaq's listing standards, which are common benchmarks for publicly traded companies.

Corporate Governance

Legal Proceedings

• Engaged counsel to pursue legal remedies against individuals or groups disseminating false and misleading information, defaming the company and its executives.
• Taking steps to file a "John Doe" lawsuit to identify and hold accountable those responsible for defamation and libel.
• Investigating indications of a significant naked short position in the company's common stock, potentially involving unlawful manipulation, and committed to pursuing legal remedies.

Stakeholder Impact

• Shareholders face significant risk of delisting, potential loss of liquidity, and depressed stock prices if moved to the OTC market. The reverse stock split aims to protect listing but reduces the number of shares held. Legal action aims to protect shareholder value from manipulation.
• Employees' company stability and future prospects are tied to successful resolution of listing issues and business growth.
• Customers will see continued service delivery and expansion, particularly in critical sectors like healthcare.
• Regulatory Authorities (Nasdaq, SEC) are engaged through the appeal process and ongoing compliance requirements.

Next Steps

• Proceed with the appeal process to the Nasdaq Hearings Panel.
• Implement the 30:1 reverse stock split, expected on October 27, 2025.
• Continue legal proceedings, including a "John Doe" lawsuit, against individuals involved in defamation and potential naked short selling.
• Announce further expansions and contracts in the coming quarters.
• If delisted, potentially apply to list shares on the over-the-counter market.

Key Dates

Recommendation

The immediate threat of Nasdaq delisting, despite the appeal, presents a severe risk to liquidity and investor confidence. The 30:1 reverse stock split is a reactive measure to address a symptom (low bid price) rather than the underlying issues that led to it. While new contracts and legal action against manipulation are positive, they are overshadowed by the existential threat to the company's public market access. The potential move to a less liquid over-the-counter market would likely depress the stock price further. Given the high uncertainty and significant downside risk, a seasoned investor would likely recommend selling to avoid further potential losses.

Keywords

Cycurion, CYCU, Nasdaq delisting, reverse stock split, cybersecurity, legal action, naked short selling, defamation, new contracts, recurring revenue, financial compliance, stock market, corporate governance, investor confidence, cyber defense, ARx platform